泰德医药的联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人是摩根 士丹利、中信证券，联席账簿管理人及联席牵头经办人是光大证券国际、发利证券有限公司、东吴证券 (香港)。 泰德医药的最终发售价为30.6港元，所得款项总额为514.08百万港元，扣除基于最终发售价的估 计应付上市开支85.31百万港元，所得款项净额为428.77百万港元。 泰德医药的基石投资者分别为石药和Welight Capital。 中国经济网北京11月21日讯 泰德医药(03880.HK)港股今日收报28.04港元，跌幅6.53%，今日盘中 最低价26.76港元，创上市以来最低价。目前该股处于破发状态，上市以来累计跌幅8.37%。 泰德医药2025年6月30日在港交所上市，最终发售价及配发结果公告显示，泰德医药发售股份数目 16,800,000股H股，其中，香港公开发售的发售股份数目(经重新分配调整)8,400,000股H股，国际发售 的发售股份数目(经重新分配调整)8,400,000股H股。 ...

Summary of Key Points Core Viewpoint - As of November 21, 14 stocks reached their 52-week highs, with Hengfa Optical (01134), Chaowei Holdings (08059), and Cassava Resources (00841) leading the gains at 42.11%, 30.56%, and 22.49% respectively [1]. 52-Week Highs - Hengfa Optical (01134) closed at 0.375, with a peak price of 0.540, marking a 42.11% increase [1]. - Chaowei Holdings (08059) closed at 0.030, reaching a high of 0.047, reflecting a 30.56% rise [1]. - Cassava Resources (00841) closed at 0.200, with a maximum price of 0.207, indicating a 22.49% increase [1]. - Other notable stocks include Sibor Systems (08319) at 15.04%, MOS HOUSE (01653) at 11.46%, and Tianjin Jianfa (02515) at 5.19% [1]. 52-Week Lows - China Pengfei Group (03348) reached a low of 1.100, down 20.09% from its peak [1]. - China Information Technology (08178) closed at 0.285, reflecting a 19.35% decrease [1]. - XL Ernan Strategy - U (09799) saw a decline of 14.27% [1]. - Other significant declines include Hesai - W (02525) at -10.54% and MBC Bitcoin - U (03425) at -9.09% [1]. Additional Notable Stocks - Stocks like MBC Bitcoin (03430) and Tongyuan Kang Pharmaceutical - B (02410) also experienced declines of 6.64% and 6.62% respectively [2]. - The overall trend indicates a mix of significant gains in certain stocks while others are facing substantial losses, reflecting a volatile market environment [1][2].

Core Viewpoint - The article highlights the insider trading activities of the actual controller and former financial director of Nanwei Co., Ltd., who sold shares to avoid losses before the company's stock was suspended due to financial misconduct and audit issues [2][3]. Group 1: Insider Trading Details - The actual controller Li Ping and former financial director Xiang Qinhua sold a total of 8.184 million shares for approximately 47.97 million yuan between March 14 and March 28, 2023, just before the negative audit report was disclosed [5]. - Following the audit report's negative opinion, Nanwei's stock price dropped from 5.51 yuan to 4.26 yuan over five consecutive trading days, indicating that Li and Xiang successfully exited before the price decline [5]. - The Jiangsu Securities Regulatory Bureau calculated that Li Ping avoided losses of 11.77 million yuan and Xiang Qinhua avoided losses of 101,700 yuan, leading to a total penalty of approximately 48.71 million yuan for both individuals [5][6]. Group 2: Financial Misconduct Background - The insider trading was rooted in the actual controller's misuse of company funds, with a total of 336 million yuan being misappropriated from bank loans through intermediaries to related parties from March 2020 to December 2022 [7][8]. - The misappropriation of funds represented significant percentages of Nanwei's net assets, with figures reaching 20.61% in 2021 and 11.11% in 2022 [8]. - The company faced a total penalty of over 57 million yuan due to the financial misconduct and insider trading activities [9]. Group 3: Shareholding and Pledge Situation - As of September 24, 2023, Li Ping held 119 million shares, representing 41.12% of the company, with 73.54% of his shares pledged, amounting to 30.24% of the total share capital [10]. - Nanwei stated that the risks associated with Li Ping's share pledges are controllable, and he plans to address potential margin call risks through various financial strategies [11].

Core Viewpoint - The case of insider trading involving Nanwei Co., Ltd. has resulted in significant penalties for its controlling shareholder and former CFO, totaling 36.83 million yuan, highlighting the consequences of using insider information to avoid potential losses [1][4][9]. Group 1: Insider Trading Case - The Jiangsu Securities Regulatory Commission issued administrative penalties against Li Ping and Xiang Qinhua for insider trading, with Li Ping being fined 35.33 million yuan and Xiang Qinhua 1.5 million yuan [1][4]. - Li Ping and Xiang Qinhua utilized insider information to sell shares of Nanwei Co., Ltd. to avoid losses, with Li Ping selling 8.184 million shares for 47.97 million yuan, avoiding losses of 11.77 million yuan, and Xiang Qinhua selling 54,000 shares for 340,500 yuan, avoiding losses of 101,700 yuan [9]. Group 2: Company Background and Financial Performance - Nanwei Co., Ltd. specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, first aid kits, and sports protection products, and has been publicly listed since 2017 [10]. - The company has faced significant challenges, including continuous losses for four consecutive years, with net profits of -22.76 million yuan, -14.65 million yuan, -147 million yuan, and -191 million yuan from 2021 to 2024 [10]. - In the first three quarters of 2025, the company reported revenue of 447 million yuan, a year-on-year decrease of 1.7%, and a net profit loss of 24.93 million yuan, a decrease of 87.25% year-on-year, attributed to intense market competition and rising costs [11].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 2. ...

Core Viewpoint - The company, Jiangsu Nanwei Medical Co., Ltd., is facing regulatory scrutiny due to insider trading activities involving its actual controller and former financial director, which has led to significant financial penalties but is stated not to affect the company's operations or listing status [2][4]. Group 1: Regulatory Actions - Li Ping, the actual controller and chairman, sold 8.184 million shares of Nanwei Co. during the sensitive period, resulting in a transaction amount of 47.9678 million yuan and an avoidance of losses amounting to 11.7767 million yuan [2]. - Xiang Qinhua, the former financial director, sold 54,000 shares during the same period, with a transaction amount of 340,500 yuan and an avoidance of losses of 101,700 yuan [2]. - The Jiangsu Regulatory Bureau decided to confiscate illegal gains of 11.7767 million yuan from Li Ping and impose a fine of 35.33 million yuan, while Xiang Qinhua will have 101,700 yuan confiscated and face a fine of 1.5 million yuan [2]. Group 2: Company Performance - Nanwei Co. reported a revenue of approximately 447 million yuan for the first three quarters of 2025, reflecting a year-on-year decrease of 1.7% [3]. - The net loss attributable to shareholders for the same period was approximately 24.93 million yuan, with a basic earnings per share loss of 0.086 yuan [3]. - As of November 4, the company's stock price was 6.84 yuan, with a total market capitalization of 2 billion yuan [3]. Group 3: Company Overview - Nanwei Co. specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [3]. - The company has established a strong partnership with Yunnan Baiyao Group, becoming the exclusive supplier of certain products [3].

Core Points - The chairman and former financial director of Nanwei Co., Ltd. were penalized for insider trading, with total fines and confiscated profits exceeding 48.7 million yuan [2][3]. Group 1: Insider Trading Penalties - Li Ping, the actual controller and chairman, sold 8.184 million shares of Nanwei Co., Ltd. during the sensitive period, with a transaction amount of 47.9678 million yuan, avoiding losses of 11.7767 million yuan [5]. - Xiang Qinhua, the former financial director, sold 54,000 shares during the same period, with a transaction amount of 340,500 yuan, avoiding losses of 101,700 yuan [5]. - The Jiangsu Regulatory Bureau decided to confiscate Li Ping's illegal gains of 11.7767 million yuan and impose a fine of 35.33 million yuan, while Xiang Qinhua faced confiscation of 101,700 yuan and a fine of 1.5 million yuan [5]. Group 2: Company Operations and Financial Performance - Nanwei Co., Ltd. primarily engages in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [6]. - As of the end of Q3 2025, the company reported revenue of approximately 447 million yuan, a year-on-year decrease of 1.7%, and a net loss attributable to shareholders of 24.93 million yuan, further widening the loss [8]. - Li Ping, aged 65, is the largest shareholder of Nanwei Co., Ltd., holding 119 million shares, accounting for 41.12% of the total shares [6][7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 2. ...

Core Points - Ted Pharmaceuticals (03880.HK) announced the resignation of Li Zhongcheng as co-secretary, authorized representative, and legal process agent effective September 26, 2025 [1] - Wu Dongcheng has been appointed as the new co-secretary, authorized representative, and legal process agent effective September 26, 2025, following Li Zhongcheng's resignation [1] - Li Lingmei will continue to serve as the other co-secretary [1]

Core Viewpoint - Ted Medical (03880) announced the resignation of Mr. Li Zhongcheng from multiple positions effective September 26, 2025 [1] Group 1 - Mr. Li Zhongcheng will resign as (i) Co-Company Secretary; (ii) Authorized Representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) Representative for receiving legal documents and notifications in Hong Kong as per Listing Rule Section 19A.13(2) and the Companies Ordinance Chapter 622 [1] - Mr. Wu Dongcheng has been appointed as Co-Company Secretary, Authorized Representative, and Legal Process Agent effective September 26, 2025 [1] - Ms. Li Lingmei will continue to serve as another Co-Company Secretary [1]